Dustin J. Maly

Dustin J. Maly

Auto-generated profile, based on publicly available information

Dustin J. Maly

Department of Chemistry, University of Washington, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Cell
Verified
Journal Article
Closed access
RGRajarshi Ghosh
Rajarshi Ghosh
LWLikun Wang
Likun Wang
EWEric S. Wang
Eric S. Wang
BPB. Gayani K. Perera
B. Gayani K. Perera
Aeid IgbariaAeid Igbaria
Aeid Igbaria
FPFeroz R. Papa
Feroz R. Papa

1 April 2017 in Cell Metabolism
Verified
Journal Article
Closed access
SMShuhei Morita
Shuhei Morita
SVS. Armando Villalta
S. Armando Villalta
HFHannah C. Feldman
Hannah C. Feldman
ARAmes C. Register
Ames C. Register
WRWendy Rosenthal
Wendy Rosenthal
FPFeroz R. Papa
Feroz R. Papa

17 October 2014 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DMDustin J Maly
Dustin J Maly
FPFeroz R Papa
Feroz R Papa

21 October 2012 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
LWLikun Wang
Likun Wang
BPB Gayani K Perera
B Gayani K Perera
SHSanjay B Hari
Sanjay B Hari
BBBarun Bhhatarai
Barun Bhhatarai
BBBradley J Backes
Bradley J Backes
DMDustin J Maly
Dustin J Maly
A kinase inhibitor based on a known type II inhibitor allosterically inhibits the RNase activity of IRE1α in vitro and in cells via the ATP-binding site in the kinase domain. Under endoplasmic reticulum stress, unfolded protein accumulation leads to activation of the endoplasmic reticulum transmembrane kinase/endoRNase (RNase) IRE1α. IRE1α oligomerizes, autophosphorylates and initiates splicing of XBP1 mRNA, thus triggering the unfolded protein response (UPR). Here we show that IRE1α's kinase-controlled RNase can be regulated in two distinct modes with kinase inhibitors: one class of ligands occupies IRE1α's kinase ATP-binding site to activate RNase-mediated XBP1 mRNA splicing even without upstream endoplasmic reticulum stress, whereas a second class can inhibit the RNase through the same ATP-binding site, even under endoplasmic reticulum stress. Thus, alternative kinase conformations stabilized by distinct classes of ATP-competitive inhibitors can cause allosteric switching of IRE1α's RNase—either on or off. As dysregulation of the UPR has been implicated in a variety of cell degenerative and neoplastic disorders, small-molecule control over IRE1α should advance efforts to understand the UPR's role in pathophysiology and to develop drugs for endoplasmic reticulum stress–related diseases.

15 March 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MSMarkus August Seeliger
Markus August Seeliger
PRPratistha Ranjitkar
Pratistha Ranjitkar
CKCorynn Kasap
Corynn Kasap
YSYibing Shan
Yibing Shan
DSDavid E. Shaw
David E. Shaw
DMDustin J. Maly
Dustin J. Maly
Imatinib is an inhibitor of the Abl tyrosine kinase domain that is effective in the treatment of chronic myelogenic leukemia. Although imatinib binds tightly to the Abl kinase domain, its affinity for the closely related kinase domain of c-Src is at least 2,000-fold lower. Imatinib recognition requires a specific inactive conformation of the kinase domain, in which a conserved Asp-Phe-Gly (DFG) motif is flipped with respect to the active conformation. The inability of c-Src to readily adopt this flipped DFG conformation was thought to underlie the selectivity of imatinib for Abl over c-Src. Here, we present a series of inhibitors (DSA compounds) that are based on the core scaffold of imatinib but which bind with equally high potency to c-Src and Abl. The DSA compounds bind to c-Src in the DFG-flipped conformation, as confirmed by crystal structures and kinetic analysis. The origin of the high affinity of these compounds for c-Src is suggested by the fact that they also inhibit clinically relevant Abl variants bearing mutations in a structural element, the P-loop, that normally interacts with the phosphate groups of ATP but is folded over a substructure of imatinib in Abl. Importantly, several of the DSA compounds block the growth of Ba/F3 cells harboring imatinib-resistant BCR-ABL mutants, including the Thr315Ile “gatekeeper” mutation, but do not suppress the growth of parental Ba/F3 cells. [Cancer Res 2009;69(6):2384–92

7 July 2010 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RMRyan C. Murphy
Ryan C. Murphy
KOKayode K. Ojo
Kayode K. Ojo
ELEric T. Larson
Eric T. Larson
ACAlejandro Castellanos-Gonzalez
Alejandro Castellanos-Gonzalez
BPB. Gayani K. Perera
B. Gayani K. Perera
DMDustin J. Maly
Dustin J. Maly